SEC Comment Letter 0000000000-24-013597 to Jabez Biosciences, Inc. (CIK 0002038185)
Jabez Biosciences, Inc. (CIK 0002038185)
Date: Dec. 10, 2024 · CIK: 0002038185 · Accession: 0000000000-24-013597
AI Filing Summary & Sentiment
File numbers found in text: 024-12509
Letter
December 10, 2024 Tamara Jovonovich Chief Executive Officer Jabez Biosciences, Inc. 6393 Blackstone Dr. Zionsville, IN 46077 Re:Jabez Biosciences, Inc. Amendment No. 3 to Offering Statement on Form 1-A Filed December 3, 2024 File No. 024-12509 Dear Tamara Jovonovich: We have reviewed your amended offering statement and have the following comment. Please respond to this letter by amending your offering statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your offering statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our November 27, 2024 letter. Amendment No. 3 to Offering Statement on Form 1-A Regulatory Process, page 23 1.We note your response to prior comment 1 and reissue. You state that performance of clinical trials in accordance with good clinical practice is required. Please expand your disclosure to provide further details regarding the regulatory structure of the clinical trials referenced. As an example only, if your product candidate JBZ-001 must undergo Phase 1, 2, and 3 of clinical trials please provide a description of what each phase entails.
December 10, 2024 Page 2 Please contact Christine Torney at 202-551-3652 or Mary Mast at 202-551-3613 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Chris Edwards at 202-551- 6761 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jim Byrd
Show Raw Text
December 10, 2024
Tamara Jovonovich
Chief Executive Officer
Jabez Biosciences, Inc.
6393 Blackstone Dr.
Zionsville, IN 46077
Re:Jabez Biosciences, Inc.
Amendment No. 3 to Offering Statement on Form 1-A
Filed December 3, 2024
File No. 024-12509
Dear Tamara Jovonovich:
We have reviewed your amended offering statement and have the following comment.
Please respond to this letter by amending your offering statement and providing the
requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your offering statement and the information you
provide in response to this letter, we may have additional comments. Unless we note
otherwise, any references to prior comments are to comments in our November 27, 2024
letter.
Amendment No. 3 to Offering Statement on Form 1-A
Regulatory Process, page 23
1.We note your response to prior comment 1 and reissue. You state that performance of
clinical trials in accordance with good clinical practice is required. Please expand your
disclosure to provide further details regarding the regulatory structure of the clinical
trials referenced. As an example only, if your product candidate JBZ-001 must
undergo Phase 1, 2, and 3 of clinical trials please provide a description of what each
phase entails.
December 10, 2024
Page 2
Please contact Christine Torney at 202-551-3652 or Mary Mast at 202-551-3613 if
you have questions regarding comments on the financial statements and related
matters. Please contact Doris Stacey Gama at 202-551-3188 or Chris Edwards at 202-551-
6761 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jim Byrd